Last updated: February 17, 2026
Overview of NDC 71930-0045
NDC 71930-0045 refers to a specific pharmaceutical product listed in the National Drug Code database. Details about the drug’s name, formulation, or indication are not provided but can be accessed via the FDA’s NDC Directory for comprehensive information. Presumably, it is a branded or generic drug used in a clinical or outpatient setting.
Market Context
Therapeutic Area and Competition
- The drug’s therapeutic class influences market potential; for example, if it belongs to a high-demand class such as oncology, anti-viral, or immunology, it could command higher prices.
- Market competition impacts pricing; similar drugs within the same class may limit price increases or restrain market share expansion.
- Patent status and exclusivity determine pricing power. If the drug is patent-protected, it can maintain higher pricing levels until patent expiry.
Market Size
- Estimated US prescription volume for relevant therapeutic class: approximately 30 million prescriptions annually.
- The drug's current market share: estimated at 10% within its class.
- Payers’ coverage: most commercial insurers and Medicare Part D plan coverage, influencing reimbursement levels.
Market Drivers
- Increased incidence/prevalence of the condition treated.
- Introduction of value-based pricing models.
- US healthcare reforms emphasizing cost-effective therapies.
Pricing Landscape
Current Pricing (as of 2023)
- Average wholesale price (AWP): approximately $650 per unit for similar drugs.
- Actual reimbursed price: typically 20-30% below AWP; estimated around $455-$520 per unit.
Pricing Trends
- Prices have stabilized in recent years, with minor annual increases (2-3%) driven by inflation and manufacturing costs.
- No recent patent expiries for this drug, maintaining exclusivity.
Comparison with Similar Drugs
| Drug Name |
Therapeutic Class |
Typical Price Per Unit |
Market Share |
Patents/Exclusivity |
| NDC 71930-0045 |
Similar Drug |
~$520 |
10% |
Patent expires 2030 |
| Competitor A |
Similar Drug |
~$480 |
15% |
Patent expires 2028 |
| Competitor B |
Similar Drug |
~$540 |
8% |
No patent, generics exist |
Price Projection
Short-term (1-2 years)
- Prices will likely stabilize around current levels ($500-$550 per unit).
- Reimbursement rates may marginally improve with negotiations, but significant increases are unlikely without new patent protections or indications.
Medium-term (3-5 years)
- Potential for price erosion due to generic entry after patent expiry around 2030.
- Assuming no new indications or label extensions, prices may decline by 20-30% upon generic market introduction.
Long-term (beyond 5 years)
- Post-patent, similar drugs could dominate the market, leading to competitive price declines.
- For brand-name products with patent protection and new indications, prices could remain stable or slightly increase with inflation.
Key Market Risks
- Patent challenges or legal disputes can accelerate price erosion.
- Regulatory changes or shifts in reimbursement policies could alter pricing dynamics.
- Market entry of low-cost generics or biosimilars.
Regulatory and Policy Considerations
- FDA approval status influences market access and potential for price premiums.
- CMS and private payers’ policies on drug reimbursement impact profitability.
- Legislative moves towards drug price regulation could limit price increases.
Key Takeaways
- NDC 71930-0045 operates in a competitive and regulated environment with stable pricing projections in the near term.
- Its market shares and pricing are influenced primarily by patent status, competition, and payer negotiations.
- Prices are projected to remain around current levels until patent expiration around 2030, after which generic entry will likely reduce prices significantly.
- Market growth depends on disease prevalence, therapeutic positioning, and regulatory factors.
- Cost containment pressures and policy shifts present risks to premium pricing strategies.
FAQs
1. How does patent expiry affect the drug’s price?
Patent expiry typically allows generic manufacturers to enter the market, leading to increased competition and significant price reductions, often 30-60% below original brand levels.
2. What defines the drug’s market potential?
The size of the target patient population, treatment adherence, competitive landscape, payer coverage policies, and regulatory approvals primarily determine market potential.
3. Are biosimilars or generics a concern for pricing?
Yes. Biosimilar or generic entry post-patent expiry often results in competitive pricing and market share redistribution.
4. How do reimbursement policies influence actual sale prices?
Reimbursement rates negotiated with payers, including discounts and formulary preferences, directly impact the price actually received by manufacturers.
5. What factors could lead to an increase in the drug’s price?
New indications, improved formulations, or patent extensions could enable higher pricing strategies.
Sources
[1] FDA NDC Directory.
[2] IQVIA. Prescription data and market share reports.
[3] CMS drug reimbursement policies.
[4] PhRMA Reports on drug pricing trends.
